Next-generation off-the-shelf and precision viral vector neoantigen cancer immunotherapies

Marina joined Nouscom in 2016 from Versant Ventures. Before Versant, she headed up the Global Neurodegeneration portfolio for Novartis Neuroscience and lead development of companion diagnostics for Novartis Oncology. She received her Ph.D. in Organic Chemistry from Yale University.

Rick joined Nouscom in September 2020 from Johnson and Johnson Innovation where he was the Global Oncology Transaction Lead responsible for external collaborations and licensing of transformational preclinical assets. Previously he had responsibility for direct healthcare investments at Wellcome Trust, and has led business and corporate development for private and public biotechnology companies.

Sven joined Nouscom as Vice President Clinical Development in October 2021. Prior to joining the company, Sven held Senior Clinical Development positions in oncology at Incyte, Novartis, OSI Pharmaceuticals and AstraZeneca. Previously he held an academic position at the University Health Network in Toronto, Canada

Elisa was formerly a Research Scientist at IRBM/Merck, where she worked on immunological aspects of Hepatitis C infection and was subsequently appointed Group Leader in Oncology. She joined Okairos in 2010 as Clinical Director of the infectious disease vaccine programmes.

Tiffany has 15 years of experience in finance including investments, global treasury, and investor relations. Prior to joining Nouscom in 2019, she held leadership roles with a U.S. based Fortune 500 company where she oversaw complex finance facilities and debt issuances, managed large hedge portfolios, and cultivated investor relationships. Tiffany received her B.A. and M.A. in Mathematics.

Loredana was GMP head at Okairos/ Reithera since 2010 where she oversaw all the manufacturing campaigns for the production of APIs for both infectious diseases  and advanced therapies. With extensive experience in developing technical operations conducted in compliance with Good Manufacturing Practice, she joined Nouscom in April 2020 as Technical Director.

She has more than 15 years of experience in the field of HR and business management. Before joining, she was General Manager in ReiThera (ex Okairos) and worked as HR and Admin in MSD (IRBM site).

Morena has more than 15 years’ experience in Immunology. She joined Nouscom in 2016 as Senior group leader of the Immunology Department; she currently leads the Immunology team, drives company interactions with external collaborators for the evaluation of genetic vaccine platforms in preclinical models and liaises with internal teams to design immunogenicity evaluation strategies.

Göran spent 35 years in the pharmaceutical industry as head of R&D and in general management. He is now board director and chairman of biotech companies in US, EU and Asia. He is a physician by training.

Marina joined Nouscom in 2016 from Versant Ventures. Before Versant, she headed up the Global Neurodegeneration portfolio for Novartis Neuroscience and lead development of companion diagnostics for Novartis Oncology. She received her Ph.D. in Organic Chemistry from Yale University.

Andrew is an Operating Partner at Versant Ventures and has been the Chief Operating Officer at Ridgeline Discovery since 2018. Ridgeline is Versant’s Discovery Engine which creates and operates Versant-financed innovative biotech companies in Basel, Switzerland.

Joachim joined LSP in 2002, and is currently a Managing Partner and co-owner of the firm. He has facilitated the growth and development of a large number of companies by leveraging his scientific and pharmaceutical expertise, and extensive global network.

Scott joined 5AM Ventures in 2003 as a Venture Partner and became a Managing Partner in 2004. He has over three decades of healthcare management experience and has entered multiple drug candidates into clinical trials.

Hakan started his investment career at Atlas Venture where he was part of the investment team in London focusing on global investment opportunities in healthcare and medical technologies across US, Europe and Asia.

Sofia joined Andera Partners in 2009 and is currently a Partner in the Andera Life Sciences team. Prior to Andera Partners, Sofia was part of the Life Sciences team of L.E.K. Consulting London having started her career in R&D with Boston-based Eyetech Pharmaceuticals, Inc.

He has more than 15 years of experience in Life Science investments. Thibaut started his career as a Scientist in a company developing immunotherapies for cancer.

Jean-Paul is a Director of Vaximm AG and a member on Curevac independent Advisory Board. He was instrumental in developing several licensed vaccines and served as the Head of Research at GSK Vaccines.

Dr. Gallagher has over 20 years of experience within large, global pharmaceutical R&D organizations and emerging biopharmaceutical companies. Throughout his career, he has led end-to-end drug development programs that have resulted in the approval of multiple innovative medicines, ranging from small molecules to biologics across several therapeutic areas, including oncology and immunology.

Doug joined Revelation Partners in 2020.  With seventeen years of investment experience, Doug focuses on biopharma, diagnostics, and medical device investments.  Over his career Doug has invested over $150 million in venture backed companies.  At Revelation, he has recently invested in Aspen Neurosciences, Dren Bio, Endeavor Biomedicines, Hotspot Therapeutics, and Strata Oncology.

Paolo is Managing Partner at XGEN Venture and is board member for TES Pharma, NanoPhoria and Genespire and board observer for Nouscom and iOnctura. Before co-founding XGEN in 2021, he was in Genextra since its inception in 2004, serving as CEO up to 2022. 

Giovanni is Partner of the Biotech Fund at Indaco Venture Partners. He has more than 20 years of experience in drug discovery and development. Previously he led the biology unit of Intercept Pharmaceuticals. He received his Ph. D. in Oncology and his specialization in Microbiology and Virology at the University of Perugia.

Paolo is the Chief Executive Officer and Managing Director of Angelini Ventures. He is currently a board member of Argobio and Extend, an observer board member of Pretzel Therapeutics, GenEp, and Arclight Therapeutics, and a member of the investment committee of the Angelini Lumira Bioscience Fund.

Leading the Biotech team at Panakes Partners since 2021, Dr. Rob Woodman has global experience in biotech and pharma gained in both institutional and corporate venture firms, encompassing de novo start-up through to growth investments, with a track record of value creation in all of these settings as demonstrated by multiple acquisitions and NASDAQ listings of the companies he has invested in.

More than 20 years of experience in operational leadership and venture capital, both in Italy and abroad, in high-tech sectors with a focus on value creation and exit strategies.
Mario was Managing Director of Samsung NEXT, Samsung’s corporate venture fund with a focus on technological scale-ups, and a member of the investment team at Imperial Innovations, a London-listed fund focused on the DeepTech sector acquired by IP Group.